Contract research projects
ATHRO 2
Duration: 2014–2015
Contracting authority: Czech Society of Cardiology
Terminated survey of patient compliance and the administration of antiplatelet therapy in patients with acute coronary syndrome who have been hospitalised in PCI centres all over the Czech Republic.
KELLY
Project start: 2014
Contracting authority: Society of Czech Pathologists
Registry of EGFR mutation testing results in patients with non-small-cell lung cancer (NSCLC) in the Czech Republic.
POPE
Duration: 2014–2018
Contracting authority: COPD PLATFORM
Clinical registry of patients with chronic obstructive pulmonary disease (COPD) in Central and Eastern Europe.
CHOPN
Project start: 2013
Contracting authority: Czech Pneumological and Phthisiological Society
Non-interventional multicentre observational prospective database focusing on the collection and analysis of data on real mortality and morbidity in an unselected population of COPD patients.
Melanom
Project start: 2013
Contracting authority: Czech Society for Oncology
Clinical registry of melanoma patients who have been treated with dabrafenib (Tafinlar®), ipilimumab (Yervoy®), nivolumab (Opdivo®), trametinib (Mekinist®), pembrolizumab (Keytruda®) and/or vemurafenib (Zelboraf®).
PET/CT-CZ(Q)
Duration: 2013–2014
Contracting authority: Czech Society for Radiation Oncology, Biology and Physics
Terminated project developing a data background for the monitoring of numbers and indications of PET/CT scans in the clinical practice of Czech health care facilities.
OVARIA
Duration: 2012–2018
Contracting authority: Czech Society for Oncology
Clinical registry of ovarian cancer patients who have been treated with bevacizumab (Avastin®) and/or olaparib (Lynparza®).
Breast
Duration: 2011–2018
Contracting authority: Czech Society for Oncology
Clinical registry of breast cancer patients who have been treated with trastuzumab (Herceptin®), lapatinib (Tyverb®), bevacizumab (Avastin®) and/or everolimus (Afinitor®).
Corect
Duration: 2011–2018
Contracting authority: Czech Society for Oncology
Clinical registry of colorectal cancer (CRC) patients who have been treated with cetuximab (Erbitux®), bevacizumab (Avastin®) and/or panitumumab (Vectibix®).
Tulung
Project start: 2011
Contracting authority: Czech Society for Oncology
Clinical registry of non-small cell lung cancer (NSCLC) patients who have been treated with bevacizumab (Avastin®), erlotinib (Tarceva®), gefitinib (Iressa®), pemetrexed (Alimta®), afatinib (Giotrif®) and/or nintedanib (Vargatef®).
Magister
Duration: 2011–2018
Contracting authority: Society of Czech Pathologists
Terminated registry of morphologically examined breast cancers, with particular emphasis on the collection of data regarding the examination of HER2/neu status in the Czech population.
Pemetrexed
Project start: 2009
Contracting authority: Czech Society for Oncology
Clinical registry of pleural mesothelioma patients who have been treated with pemetrexed (Alimta®).
Amadeus
Duration: 2008–2018
Contracting authority: Czech Society of Ophthalmology
Clinical registry of patients suffering from age-related macular degeneration (AMD) or diabetic macular oedema (DMO) who have been treated with anti-VEGF medications.
RenIS
Duration: 2007–2018
Contracting authority: Czech Society for Oncology
Clinical registry of kidney cancer patients who have been treated with bevacizumab (Avastin®), everolimus (Afinitor®), pazopanib (Votrient®), sorafenib (Nexavar®), sunitinib (Sutent®) and/or temsirolimus (Torisel®).
reGISTer
Project start: 2006
Contracting authority: Czech Society for Oncology
Clinical registry monitoring the epidemiology of gastrointestinal stromal tumours (GIST) as well as therapeutic approaches and treatment results in GIST patients in the Czech Republic and Slovakia.
CAMELIA – Chronic MyEloid LeukaemIA
Project start: 2004
Contracting authority: Czech Society of Haematology, Slovak Society of Haematology and Transfusiology
International clinical registry of patients with chronic myeloid leukaemia.
ATTRA
Project start: 2002
Contracting authority: Czech Rheumatological Society
Multicentric system for the assessment of the progress and results of biological therapy of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus.
